Hana Algul
Experienced in Fibrolamellar Carcinoma

Hana Algul

Ismaninger Str. 22, 
Munich, BY, DE 
Experienced in Fibrolamellar Carcinoma
Ismaninger Str. 22, 
Munich, BY, DE 
OverviewLocationsClinical Research

Overview

Hana Algul practices in Munich, Germany. Ms. Algul is rated as an Experienced expert by MediFind in the treatment of Fibrolamellar Carcinoma. Her top areas of expertise are Pancreatic Cancer, Hereditary Pancreatitis, Acute Pancreatitis, Lithotripsy, and Endoscopy.

Her clinical research consists of co-authoring 141 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article in the study of Fibrolamellar Carcinoma.

Gender
Female

Locations

Ismaninger Str. 22, Munich, BY 81675, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase 3, Randomized, Double-Blind Study of Pamrevlumab or Placebo in Combination With Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX as Neoadjuvant Treatment in Patients With Locally Advanced, Unresectable Pancreatic Cancer
A Phase 3, Randomized, Double-Blind Study of Pamrevlumab or Placebo in Combination With Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX as Neoadjuvant Treatment in Patients With Locally Advanced, Unresectable Pancreatic Cancer
Enrollment Status: Completed
Publish Date: November 05, 2024
Intervention Type: Drug
Study Drugs: Pamrevlumab, Gemcitabine, Nab-paclitaxel, FOLFIRINOX
Study Phase: Phase 3
A Phase 1 Study of an ERK1/2 Inhibitor (LY3214996) Administered Alone or in Combination With Other Agents in Advanced Cancer
A Phase 1 Study of an ERK1/2 Inhibitor (LY3214996) Administered Alone or in Combination With Other Agents in Advanced Cancer
Enrollment Status: Completed
Publish Date: November 22, 2022
Intervention Type: Drug
Study Phase: Phase 1
Study to Reduce Incidence of Post-ERCP Pancreatitis by Stent Insertion in the Main Pancreatic Duct After Unintended Cannulation of the Main Pancreatic Duct
Study to Reduce Incidence of Post-ERCP Pancreatitis by Stent Insertion in the Main Pancreatic Duct After Unintended Cannulation of the Main Pancreatic Duct
Enrollment Status: Completed
Publish Date: October 13, 2017
Intervention Type: Device
Study Phase: Not Applicable
View 2 Less Clinical Trials

141 Total Publications

An interdisciplinary approach to ensure adherence to exercise and potentially reduce adverse cardiac events in cancer patients: primers in cardio-oncology.
An interdisciplinary approach to ensure adherence to exercise and potentially reduce adverse cardiac events in cancer patients: primers in cardio-oncology.
Journal: Frontiers in oncology
Published: June 18, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Algul's expertise for a condition
ConditionClose
    View All 15 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile